Conference Coverage
Conference Coverage
Once-weekly basal insulin nears market for type 2 diabetes
“I feel that weekly insulins have the potential to become transformational as preferred options for basal insulin replacement in people with type...
Conference Coverage
ADA: Screen all with type 2 diabetes for fatty liver disease
The ADA now advises screening all adults with type 2 diabetes or prediabetes, particularly those with obesity or cardiometabolic risk factors or...
Conference Coverage
Triple-agonist retatrutide hits new weight loss highs
“I have never seen weight loss at this level” after nearly 1 year of treatment.
Latest News
SAFE algorithm detects liver disease in general population
Scoring system was developed and validated to detect clinically significant (greater than stage 2) fibrosis in patients with NAFLD in primary care...
Conference Coverage
Surgery, radioactive iodine for hyperthyroidism up survival
“I think this is something we need to take into our discussions with patients because treatment for hyperthyroidism is very much individualized...
Conference Coverage
Children with type 2 diabetes face dire complications as young adults
Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the...
Conference Coverage
Cagrilintide with semaglutide: A way to prevent diabesity?
“These data support further investigation of CagriSema in people with type 2 diabetes in longer and larger phase 3 studies.”
Conference Coverage
OASIS and PIONEER PLUS support high-dose oral semaglutide
OASIS-1 showed that “oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer...
Conference Coverage
Tackle education and mindset to reduce diabetes distress
“Diabetes distress is the emotional response to living with diabetes, the burden of relentless daily self-management, and the prospect of its long...
Conference Coverage
‘Striking’ benefit of lipid lowering in primary prevention
“If patients can’t tolerate a statin, then treat them with bempedoic acid. The bottom line is that these patients just need to be treated.”
Conference Coverage
SURMOUNT-2: Tirzepatide rings up major weight loss in type 2 diabetes
Taken together, results from SURMOUNT-1 and SURMOUNT-2 appear to make a good case for a weight-loss indication that will not depend on whether a...